Plx8394

DMEM (Invitrogen) with 10% FBS (Atlanta Biologicals) was used for 293 T cell culture and maintained in 5% CO2 at 37 °C. The ATL patient-derived cell lines MT1, ATL25, ED-40515(−), Tl-Om1, and ATLT, along with the HTLV-I cell line, MT4, were cultured in RPMI-1640 (Invitrogen) with 10% FBS in 5% CO2 at 37 °C. The ATL patient-derived cell lines, KOB, KK1, ATL55T, and ATL43T, were cultured in RPMI-1640 with 20% FBS and 50 U/ml IL-2. Cell proliferation was analyzed by XTT assays (Trevigen) or by microscopic cell counts at different times after drug treatment as indicated in the figure legends. JQ1, OTX015, and AG490 were purchased from Cayman Chemical. Dinaciclib (SCH727965), PLX8394, Sorafenib, and Ulixertinib (BVD-523) selective inhibitors were purchased from Selleckchem.

Trametinib (GSK1120212) (#S2673), PLX4720 (#S1152), PLX4032 (#S1267), PLX8394 (#S7965), AZD5991 (#S8643), MK2206 (#S1078), buparlisib (BKM120) (#S2247), and Navitoclax (#S1001) were purchased from Selleck Chemicals, LLC. DRP-1 (#8570S), BAK (#12105S), Bcl-XL (2762S), Caspase 9 (#9502S), Cleaved caspase 3 (#9661S), HSP90 (#4877S), pERK1/2 (#9101S), pRb S807/811 (#9308S), pT308 AKT (#2965S), pPRAS40 T246 (#2640S), VCAM1 (#13662S), Mcl-1 (#4572S), LAMP-1 (#9091T), Vinculin (#4650S), Tubulin (#2148S), COX-IV (#11967S), cytochrome c (#11940S) cleaved PARP (#9541) and GAPDH (#2118S) antibodies were purchased from Cell Signaling Technology. ERK2 (sc-1647) and AIF (#sc-13116) were purchased from Santa Cruz Biotechnology Inc., γH2AX (ab11174) was purchased from Abcam, Actin (A2066) was purchased from Sigma-Aldrich Co., and Bcl-2 (#51-6511GR) was purchased from BD Biosciences. Goat anti-rabbit IgG Alexa Fluor^TM 488 secondary antibody was purchased from Invitrogen.